Senicapoc: a potent candidate for the treatment of a subset of Hereditary Xerocytosis caused by mutations in the Gardos channel.

Hereditary xerocytosis (HX) is a form of stomatocytosis, a red blood cell disease characterized by impaired cation permeability and hemolytic anemia.[1][1] In HX, red blood cell (RBC) K+ permeability is largely increased compared to Na+ permeability thus resulting in a loss of KCl accompanied by